Immunomodulatory and antitumour effects of abnormal Savda Munziq on S180 tumour-bearing mice
1 Department of Drug Analysis, Xinjiang Medical University, 830011, Urumqi, Xinjiang, People’s Republic of China
2 Faculty of Traditional Uyghur Medicine, Xingjiang Medical University, 830011, Urumqi, Xingjiang, People’s Republic of China
3 Department of Pharmacology, Xinjiang Medical University, 830011, Urumqi, Xingjiang, People’s Republic of China
4 Department of Pharmacology, Univ Bordeaux, F-33000, Bordeaux, France
Citation and License
BMC Complementary and Alternative Medicine 2012, 12:157 doi:10.1186/1472-6882-12-157Published: 17 September 2012
Abnormal Savda Munziq (ASMq), a traditional uyghur medicine, has shown anti-tumour properties in vitro. This study attempts to confirm these effects in vivo and measure effects on the immune system.
Kunming mice transplanted with Sarcoma 180 cells were treated with ASMq (2–8 g/kg/day) by intra-gastric administration compared to model and cyclophosphamide (20 mg/kg/day). After the 14th day post tumour implant, thymus, liver, spleen and tumours were removed, weighed, and processed for histopathological analysis. Blood samples were also taken for haematological and biochemical analyses including TNF-α , IL-1 β and IL-2. Splenic lymphocyte function was measured with MTT; lymphocyte subpopulations were measured by flow cytometry.
ASMq treated animals had reduced tumour volume compared to model and increased concentrations of TNF-α, IL-1β and IL-2 compared to untreated and to cyclophosphamide-treated animals. No histopathological alterations were observed. The absence of viable S180 cells and the presence of necrotic cells and granulation tissue were observed in tumour tissue of treated animals. The effect on T lymphocytes was unclear.
ASMq confirmed in vivo anti-tumour effects observed in vitro, which may be at least in part mediated by increased immune activity.